{
}
CRISPR technology is transforming genetic research and applications, with the global market projected to grow from USD 3.2 billion in 2023 to USD 15.0 billion by 2033, at a CAGR of 16.7%. North America leads in market share, driven by advancements in healthcare and agriculture, while ethical and regulatory challenges persist. The technology enhances crop resilience and supports biomedical research, paving the way for innovative therapies and sustainable agricultural practices.
A grant is set to advance CRISPR-based gene therapy targeting neurological disorders, with the global market projected to grow from USD 4.14 billion in 2023 to USD 18.84 billion by 2034, driven by rising demand for gene therapy and advancements in technology. The biomedical research segment leads in revenue, while North America is expected to dominate market share, with Asia Pacific showing the fastest growth. Notable collaborations, such as Vertex Pharmaceuticals and CRISPR Therapeutics, highlight the transformative potential of CRISPR in treating genetic conditions.
Editas Medicine will lay off 180 employees, about two-thirds of its workforce, as it shifts focus to “in vivo” gene editing after failing to find a partner for its sickle cell therapy. The company is ending development of its lead CRISPR medicine and will share more preclinical data in early 2025.
Editas Medicine reported a Q3 loss of $0.75 per share, slightly better than the expected loss of $0.76, but revenues plummeted to $0.06 million, missing estimates by 99.13%. The company has seen a 71.3% decline in shares this year, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions, with current consensus estimates at -$0.67 EPS and $13.31 million in revenues for the next quarter.
Editas Medicine is seeking a partner or considering out-licensing its lead gene editing therapy, reni-cel, aimed at treating sickle cell disease and beta thalassemia. This shift comes as the company pivots from previous strategies and aims to reduce spending while advancing its research. Despite promising preclinical data, Editas faces challenges in bringing reni-cel to market, prompting a focus on in vivo gene editing for future treatments.
Editas Medicine, Inc.
Companies
| Symbol | EDIT |
| Name | Editas Medicine, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MA |
| City | Cambridge |
| Zipcode | 2141 |
| Website | http://www.editasmedicine.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
CRISPR technology market poised for rapid growth and transformative advancements
Euro
United States Dollar
Editas Medicine, Inc.
CRISPR Therapeutics AG
Intellia Therapeutics, Inc.
USA
Show more
13:04 14.01.2025
advancements in crisper technology drive growth in gene editing market
United States Dollar
Vertex Pharmaceuticals Incorporated
Editas Medicine, Inc.
CRISPR Therapeutics AG
GBR
USA
Show more
17:45 13.01.2025
editas medicine lays off staff and shifts focus to in vivo gene editing
United States Dollar
bluebird bio, Inc.
CRISPR Therapeutics AG
Editas Medicine, Inc.
Baisong Mei
Gilmore O’Neill
Show more
01:00 12.12.2024
editas medicine reports quarterly loss and misses revenue expectations
14:40 04.11.2024
editas seeks partner for gene editing therapy amid strategic shift
United States Dollar
Moelis & Company
Vertex Pharmaceuticals Incorporated
Genevant Sciences
CRISPR Therapeutics AG
Editas Medicine, Inc.
USA
Gilmore O’Neill
Dae Gon Ha
Show more
17:15 22.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Finance Mergers & Acquisitions
Retail and Consumer Goods
Global Financial Events
Global Trade Developments
Industry Mergers & Acquisitions
Banking Regulations
CEO Changes
Market Analysis and Predictions
Supply Chain Management
Central Bank Actions
Workplace Trends
Government Economic Policies
Startups & Entrepreneurship
Hedge Funds & Private Equity
Financial Scams and Security
Government Policies
Domestic Politics
Countries:
Companies:
Barclays PLC
BNP Paribas SA
Tesla, Inc.
Deutsche Bank RV Global PP
Apple Inc.
Raiffeisen Bank International AG
JPMorgan Chase & Co.
Citigroup Inc.
UniCredit S.p.A.
The Goldman Sachs Group, Inc.
Strabag SE
UBS Group AG
Bank of America Corporation
Google Inc.
Morgan Stanley
Kering S.A. (ADRs)
Microsoft Corporation
Lloyds Banking Group plc
Banco BPM S.p.A.
Berner Kantonalbank AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Vietnamese Đồng
Russian Ruble
Hong Kong Dollar
United Arab Emirates Dirham
Australian Dollar
Indonesian Rupiah
Brazilian Real
Canadian Dollar
Filipino Peso
Malaysian Ringgit
South African Rand
South Korean Won
Offshore Chinese Yuan
People: